Krazati monotherapy shows significant survival benefit in KRAS G12C-mutated NSCLC Phase III Krystal -12 data

The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024

Biocon's European partner Zentiva receives approval from UK MHRA for Liraglutide

The company had earlier announced about the approval received from the MHRA for Liraglutide

Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer

First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations

Biocon to obtain approval for diabetes drug, Liraglutide in UK

Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus

Caplin Group commences operations of Rs. 150 crore oncology facility

The facility will manufacture tablets, capsules, and injections for the oncology segment

Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder

First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+

Warren Remedies commences commercial production of APIs

Akums introduces Hydroxyurea oral suspension for sickle cell disease

This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India

IFF to sell Pharma Solutions business to Roquette for US$ 2.85 billion

Pharma Solutions operates 10 research and development and/or production sites globally

Johnson Matthey sells Medical Device Components business for US$700 million to Montagu

The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol